Cassava Sciences | PTIE - Net Income


Cassava Sciences reported $-12.54M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Abbott USD 1.08B 699M Mar/2026
Amgen USD 1.33B 1.88B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
Cara Therapeutics USD -5.53M 621K Sep/2025
Cassava Sciences USD -12.54M 1.73M Dec/2025
Eisai JPY 17.18B 7.02B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Geron USD -31.14M 12.72M Dec/2025
J&J USD 5.24B 119M Mar/2026
Merck USD 2.96B 2.82B Dec/2025
Novartis USD 2.41B 1.52B Dec/2025
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025